Volume 65, Issue 2, Pages (February 2004)

Slides:

Advertisements

Similar presentations

A skeptical view of assisted home peritoneal dialysis

Advertisements

Volume 63, Issue 4, Pages (April 2003)

Volume 65, Issue 6, Pages (June 2004)

Volume 57, Issue 5, Pages (May 2000)

Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis Andrew.

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Intensive hemodialysis—keeping the faith

Use of hemodialysis and hemoperfusion in poisoned patients

Volume 70, Issue 8, Pages (October 2006)

Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis James F. Medcalf, Kevin P.G.

Confounding: What it is and how to deal with it

Volume 66, Issue 4, Pages (October 2004)

Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis Andrew.

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Volume 57, Issue 5, Pages (May 2000)

Intensive hemodialysis—keeping the faith

Continuous renal replacement therapy in the critically ill patient

The risk of hospitalization and modality failure with home dialysis

Volume 75, Issue 11, Pages (June 2009)

Section 5: Dialysis Interventions for Treatment of AKI

George A. Kaysen, Burl R. Don

Volume 63, Issue 2, Pages (February 2003)

Volume 80, Issue 9, Pages (November 2011)

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 84, Issue 1, Pages (July 2013)

N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment Martina Franz, Wolfgang Woloszczuk, Walter.

Volume 61, Issue 2, Pages (February 2002)

Volume 87, Issue 2, Pages (February 2015)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 66, Issue 1, Pages (July 2004)

Gentamicin pharmacokinetics during slow daily home hemodialysis

Pharmacokinetics of Multiple-Dose Levofloxacin in Hemodialysis Patients Shuichi Tsuruoka, MD, PhD, Noritsugu Yokota, MD, PhD, Tokie Hayasaka, RN, Tetsuo.

Volume 54, Issue 2, Pages (August 1998)

Relationship between methylmalonic acid and cobalamin in uremia

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Blood pressure targets in hemodialysis patients

Volume 67, Issue 1, Pages (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow Steve J. Schwab, Matthew J. Oliver,

The third World Kidney Day: Looking back and thinking forward

Effects of hemodialysis on cardiac function

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Alternate-day dialysis may be needed for hemodialysis patients

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

Hepatitis C treatment in patients with kidney disease

Volume 60, Issue 6, Pages (December 2001)

Volume 64, Issue 3, Pages (September 2003)

Volume 63, Issue 4, Pages (April 2003)

A man with a hole in his penis

A skeptical view of assisted home peritoneal dialysis

Serum cystatin C-immunoglobulin high-molecular-weight complexes in kidney and liver transplant patients Jesús Hermida, Rafael Romero, J. Carlos Tutor

Volume 63, Issue 2, Pages (February 2003)

Current status of maintenance hemodialysis in Beijing, China

Reply Journal of Vascular Surgery

Elevated plasma F2-isoprostanes in patients on long-term hemodialysis

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 6, Pages (December 2001)

Charles A. Herzog Kidney International

Bradley A. Warady, Mwaffek Bashir, Lynn A. Donaldson

Antonio Piccoli, Marta Codognotto Kidney International

The International Pediatric Peritonitis Registry: Starting to walk

Antioxidant therapy in hemodialysis patients: a systematic review

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Taqumpay Esmiraldo Tigcal Sacamay, W. Kline Bolton

Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin Jacek Borawski, Beata Naumnik, Michał Myśliwiec

Stephen Pastan, J. Michael Soucie, William M. McClellan

Characteristics of sudden death in hemodialysis patients

Presentation transcript:

Volume 65, Issue 2, Pages 666-674 (February 2004) Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis Katrin Annett Pöschel, Elke Bucha, Hans-ulrich Esslinger, Kristina Ulbricht, Peter Nörtersheuser, Günter Stein, Götz Nowak Kidney International Volume 65, Issue 2, Pages 666-674 (February 2004) DOI: 10.1111/j.1523-1755.2004.00433.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Mean (±2 SEM) effect-time course of activated partial thromboplastin time (aPTT) (seconds), Group II,N=10patients. S, start of sessions [hemodialysis (HD1-13); E, end of sessions (HD1-13). Anticoagulants: unfractionated heparin (UFH) for HD1-3, PEG-Hirudin for HD4-13. Blood sampling times for HD1+4+8+13: prior to HD, at 5 minutes, 30 minutes, 1hour, 2hours, 3hours, and post-dialysis. Blood sampling times for HD2+3, HD5-7 and HD9-12: pre- and post-dialysis. The intradialytic intervals (from S to E) represent a mean duration of 4.3hours; the interdialytic intervals (from E to S) represent time periods of 2 or 3days. Kidney International 2004 65, 666-674DOI: (10.1111/j.1523-1755.2004.00433.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Ecarin clotting time (ECT) (A) and activated partial thromboplastin time (aPTT) (B) versus PEG-Hirudin plasma concentration relationship. The relationship between ECT and PEG-Hirudin, based on anti IIa-activity, can be described with sufficient accuracy (r = 0.91), whereas the relationship between aPTT and PEG-Hirudin is more variable (r = 0.56). Kidney International 2004 65, 666-674DOI: (10.1111/j.1523-1755.2004.00433.x) Copyright © 2004 International Society of Nephrology Terms and Conditions